|Bid||4.50 x 1800|
|Ask||7.55 x 1000|
|Day's Range||6.25 - 6.72|
|52 Week Range||4.20 - 23.36|
|Beta (3Y Monthly)||2.52|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.00|
Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 5,000 shares of the company’s common stock, at a per share exercise price of $6.01 the closing trading price on August 7, 2019, and restricted stock units to acquire 2,625 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
- Second quarter GOCOVRI® product sales of $12.7 million; total prescriptions grew to approximately 6,160 - INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Better-than-expected performance at Technology & Equipment and growth in emerging markets are likely to aid DENTSPLY SIRONA (XRAY) in Q2 earnings.
EMERYVILLE, Calif., July 23, 2019 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 second quarter financial results on Thursday,.
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and small-cap stocks underperformed the […]
LOS ANGELES, CA / ACCESSWIRE / June 28, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or "the Company") (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK , June 27, 2019 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (ADMS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Adamas ...
LOS ANGELES, CA / ACCESSWIRE / June 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or "the Company") (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
In 2000 Gregory Went was appointed CEO of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). This analysis aims first to...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals ...
Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced a retrospective data analysis from pooled Phase 3 trials of GOCOVRI® (amantadine) extended release capsules were presented at the International Association of Parkinsonism and Related Disorders (IAPRD) World Congress, and published in the Journal of Parkinson’s Disease, online 8th May 2019.
Adamas (ADMS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The law firm of Lieff Cabraser Heimann & Bernstein, LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (ADMS), including investors who purchased Adamas common stock directly in the Company’s January 24, 2018 secondary public offering (“SPO”). Adamas investors who wish to learn more about the investigation should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.
NEW YORK, June 17, 2019 -- Levi & Korsinsky reminds investors that it has commenced an investigation of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQGM:.